B+
Bull case
25%
Probability
Target price
$205.00
Analysis reference price unavailable
Analysis 2026-05-18 · RankAlpha Sentiment Codex
DHR
DanaherDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Bioprocessing and Life Sciences recovery can persist, Diagnostics can stabilize, and the Masimo transaction can improve mix and EPS leverage if regulatory clearance and integration proceed cleanly. If those pieces hold, the stock can move closer to the Street's median target of 264.19 than the current 161.91 anchor price.
Posture
Defensive
Lead driver
Sentiment
What changed
4 setup hits (3d) with net bullish as of 2026-09-09.
What can break
Diagnostics remains the weakest segment; Q1 core growth was only 0.5%, and Cepheid's lighter respiratory season highlighted how uneven the recovery still is.
Momentum
46
Value
62
Sentiment
42
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $168.00 · Bull $205.00 · Bear $132.00Analysis 2026-05-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $228.27
Why
Momentum46 · Δ7d +8.5
Value62 · Δ7d -0.0
Sentiment42 · Δ7d +5.5
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 4 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +5.5.
Contradictions & invalidation
- • Diagnostics remains the weakest segment; Q1 core growth was only 0.5%, and Cepheid's lighter respiratory season highlighted how uneven the recovery still is.
- • If Bioprocessing and Life Sciences momentum cools, earnings support may rely too heavily on cost control, mix, or acquisition assumptions rather than broad-based organic acceleration.
- • Q1 showed that broad organic growth is still thin, with core revenue only +0.5% and Cepheid still soft.
Catalyst clock
2026-06-26
Q1 beat-and-raise kept 2026 EPS momentum intact
Lead driver: Sentiment · See AI snapshot
Momentum
46
9% active weight
Current posture
7d trendImproving
Δ7d
+8.5
Δ21d
-3.4
Value
62
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
42
62% active weight
Current posture
7d trendImproving
Δ7d
+5.5
Δ21d
-0.8
Why this grade
Composite grade D. Momentum 46.2 / Value 62.4 / Sentiment 41.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-18. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$168.00
Analysis reference price unavailable
Analysis 2026-05-18 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$132.00
Analysis reference price unavailable
Analysis 2026-05-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$142.45B
Beta
0.92
Shares Out
702.99M
P/E (TTM)
48.4
P/S (TTM)
6.85
P/FCF (TTM)
39.87
Rev YoY
+5.5%
EPS YoY
+59.3%
Gross Margin
+59.0%
Op Margin
+21.2%
Net Debt
$15.08B
Current Ratio
1.65
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data